Patent intelligence · US
US 6270781
Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
Patent details — US 6270781
- Jurisdiction
- US
- Status
- expired
- Grant date
- Aug 7, 2001
- Expiration
- Aug 2, 2021
- Applicant
- Maxim Pharmaceuticals, Inc.
- Claims
- 9
- CPC classes
- A61K, A61K31/00, A61K31/203, A61K31/4045
Quick answer
US 6270781 (Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors) is held by Maxim Pharmaceuticals, Inc.. Status: expired. Granted Aug 7, 2001. Expires Aug 2, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Maxim Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/00, A61K31/203, A61K31/4045, A61K31/417, A61K38/202
More from Maxim Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12391732
Articles comprising a silk polypeptide for antigen delivery
granted -
US 12379385
Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function
granted -
US 12318397
Methods and compositions for testosterone production
granted -
US 12290524
Methods and compositions for testosterone production
granted -
US 12171837
Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
granted -
US 12168718
Thermogelling supramolecular sponge as self-healing and biocompatible hydrogel
granted -
US 12144876
Security mechanisms for radiopharmaceutical elution system and elution process
granted -
US 12133890
Antigen-binding polypeptide targeting B7H3 and application thereof
granted
Frequently asked questions
What is US patent 6270781?
US 6270781 (Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors) is held by Maxim Pharmaceuticals, Inc.. Status: expired. Granted Aug 7, 2001. Expires Aug 2, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6270781?
Maxim Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 138 pharmaceutical patents for this assignee.
When does US 6270781 expire?
Our index shows an expiration date of Aug 2, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.